Inclusion Criteria
Concurrent Medication:
Allowed:
- Systemic or oral antibiotics.
- Experimental drugs (IND drugs) which are targeted specifically against the AIDS (group IV CDC classification) virus or stimulate the immune system.
Patients with the following conditions are included:
- AIDS or AIDS related complex (ARC) (HIV infection Group 3 or 4, CDC classification) who have had culture-proven oral candidiasis clinically cured within 7 days of study entry and are likely to be compliant for the 20 weeks of nystatin pastille prophylaxis.
- Able to follow instructions regarding the use of a pastille.
- Patients entering part II of this study (randomized double-blind) must have been clinically cured of oral candidiasis within 1 - 7 days of entry into this randomized study.
- Oral lesions such as Kaposi's sarcoma, herpes zoster, and herpes simplex can be enrolled.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Systemic candidiasis.
- Hypersensitivity to nystatin.
- Suspected or proven candidal esophagitis.
Patients with the following are excluded:
- Systemic candidiasis.
- Projected survival of less than 6 months.
- Unable to maintain a pastille in the buccal cavity for approximately 20 minutes twice a day.
- Hypersensitivity to nystatin.
- Suspected or proven candidal esophagitis.